Immunotherapy in other thoracic malignancies and uncommon populations

Jordi Remon; Benjamin Besse

doi:10.21037/tlcr-21-456

Immunotherapy in other thoracic malignancies and uncommon populations

Jordi Remon, Benjamin Besse

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

langue originale	Anglais
Pages (de - à)	2865-2867
Nombre de pages	3
journal	Translational Lung Cancer Research
Volume	10
Numéro de publication	6
Les DOIs	https://doi.org/10.21037/tlcr-21-456
état	Publié - 1 juin 2021

Accès au document

10.21037/tlcr-21-456

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{96a0ecd6de8d4d00a6e0d8bde314ec7d,

title = "Immunotherapy in other thoracic malignancies and uncommon populations",

author = "Jordi Remon and Benjamin Besse",

note = "Funding Information: tlcr-21-456). The series “Immunotherapy in other thoracic malignancies and uncommon populations” was commissioned by the editorial office without any funding or sponsorship. JR and BB served as the unpaid Guest Editors of the series and JR serves as an unpaid editorial board member of Translational Lung Cancer Research from Sep 2019 to Sep 2021. JR reports payment or honoraria from PFIZER, ASTRA-ZENECA, BMS, MSD, OSE-IMMUNOTHERAPEUTICS, travel support from ASTRA-ZENECA, participation in GENMAB, MSD, BMS and EORTC LUNG CANCER GROUP SECRETARY. BB reports grants from 4D Pharma, grants from Abbvie, grants from Amgen, grants from Aptitude Health, grants from AstraZeneca, grants from BeiGene, from Blueprint Medicines, grants from BMS, grants from Boehringer Ingelheim, grants from Celgene, grants from Cergentis, grants from Cristal Therapeutics, grants from Daiichi-Sankyo, grants from Eli Lilly, grants from GSK, grants from Inivata, grants from Janssen, grants from Onxeo, grants from OSE immunotherapeutics, grants from Pfizer, grants from Roche-Genentech, grants from Sanofi, grants from Takeda, grants from Tolero Pharmaceuticals, outside the submitted work. The authors have no other conflicts of interest to declare.",

year = "2021",

month = jun,

day = "1",

doi = "10.21037/tlcr-21-456",

language = "English",

volume = "10",

pages = "2865--2867",

journal = "Translational Lung Cancer Research",

issn = "2218-6751",

number = "6",

}

TY - JOUR

T1 - Immunotherapy in other thoracic malignancies and uncommon populations

AU - Remon, Jordi

AU - Besse, Benjamin

N1 - Funding Information: tlcr-21-456). The series “Immunotherapy in other thoracic malignancies and uncommon populations” was commissioned by the editorial office without any funding or sponsorship. JR and BB served as the unpaid Guest Editors of the series and JR serves as an unpaid editorial board member of Translational Lung Cancer Research from Sep 2019 to Sep 2021. JR reports payment or honoraria from PFIZER, ASTRA-ZENECA, BMS, MSD, OSE-IMMUNOTHERAPEUTICS, travel support from ASTRA-ZENECA, participation in GENMAB, MSD, BMS and EORTC LUNG CANCER GROUP SECRETARY. BB reports grants from 4D Pharma, grants from Abbvie, grants from Amgen, grants from Aptitude Health, grants from AstraZeneca, grants from BeiGene, from Blueprint Medicines, grants from BMS, grants from Boehringer Ingelheim, grants from Celgene, grants from Cergentis, grants from Cristal Therapeutics, grants from Daiichi-Sankyo, grants from Eli Lilly, grants from GSK, grants from Inivata, grants from Janssen, grants from Onxeo, grants from OSE immunotherapeutics, grants from Pfizer, grants from Roche-Genentech, grants from Sanofi, grants from Takeda, grants from Tolero Pharmaceuticals, outside the submitted work. The authors have no other conflicts of interest to declare.

PY - 2021/6/1

Y1 - 2021/6/1

UR - http://www.scopus.com/inward/record.url?scp=85108956770&partnerID=8YFLogxK

U2 - 10.21037/tlcr-21-456

DO - 10.21037/tlcr-21-456

M3 - Review article

AN - SCOPUS:85108956770

SN - 2218-6751

VL - 10

SP - 2865

EP - 2867

JO - Translational Lung Cancer Research

JF - Translational Lung Cancer Research

IS - 6

ER -